Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combination Therapy in Immunotherapy-Pretreated Recurrent or Metastatic Endometrial Cancer
NCT06917092Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in endometrial cancer (EC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06917092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917092.